Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma

Demirović, Alma; Džombeta, Tihana; Tomas, Davor; Spajić, Borislav; Pavić, Ivana; Hudolin, Tvrtko; Milošević, Milan; Čupić, Hrvoje; Krušlin, Božo

doi:10.1016/j.prp.2010.05.013

Cited by 14 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of MAGE-A3/4 expression was 88.2% (15/17) for oncocytoma and 38.9% (7/18) for chromophobe RCC. In addition, the incidence of NY-ESO-1 expression was 88.2% (15/17) for oncocytoma and 33.3% (6/18) for chromophobe RCC (30). In this study, although a small number of cases was evaluated, NY-ESO-1 expression was demonstrated in 33.3% (1/3) of the chromophobe cases (data not shown), a fact which was in agreement with previous studies (30).…”

Section: Discussionsupporting

confidence: 92%

“…In addition, the incidence of NY-ESO-1 expression was 88.2% (15/17) for oncocytoma and 33.3% (6/18) for chromophobe RCC (30). In this study, although a small number of cases was evaluated, NY-ESO-1 expression was demonstrated in 33.3% (1/3) of the chromophobe cases (data not shown), a fact which was in agreement with previous studies (30). We evaluated CTA expression in other types of RCC to determine its value for predicting poor prognosis or malignancy, including distinguishing between chromophobe RCC and oncocytoma.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Limited expression of cancer-testis antigens in renal cell carcinoma patients

Soga

Hori

Yamakado

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of this study was to evaluate the frequency of expression of the cancer-testis antigens (CTAs) NY-ESO-1, MAGE-A4 and SAGE, in renal cell carcinoma (RCC) patients compared to that in head and neck cancer (HNC) patients, which represent a positive control with a high incidence of CTA expression, to identify novel target antigens for immunotherapy. We prospectively examined frozen tissue samples collected from surgery or biopsy from 35 RCC and 40 HNC patients. Total RNA was extracted, and real-time reverse transcription-polymerase chain reaction (RT)-PCR was performed to determine the expression of MAGE-A4, NY-ESO-1 and SAGE. MAGE-A4 was not detected in any of the RCC samples, although a low incidence of NY-ESO-1 (5.7%; 2/35) and SAGE (2.9%; 1/35) expression was observed. No samples demonstrated co-expression of the three CTAs. By contrast, a comparatively high incidence of CTA expression was detected in squamous cell carcinoma (SCC) specimens of HNC patients. The actual incidence was 42.5% (17/40) for MAGE-A4, 20% (8/40) for NY-ESO-1 and 15% (6/40) for SAGE. The incidence of co-expression was 7.5% (3/40) for MAGE-A4 and NY-ESO-1, 7.5% (3/40) for MAGE-A4 and SAGE, 7.5% (3/40) for NY-ESO-1 and SAGE, and 2.5% (1/40) for the CTAs. The number of HNC samples positive for MAGE-A4 was significantly higher compared to that of RCC samples. The remaining two antigens, NY-ESO-1 and SAGE, were expressed at high levels in HNC compared to RCC samples. Limited frequency of CTA (NY-ESO-1, MAGE-A4 and SAGE) expression was demonstrated in RCC compared to HNC samples.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 97%

Limited expression of cancer-testis antigens in renal cell carcinoma patients

Soga

Hori

Yamakado

et al. 2012

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…BCA2, a RING H2 finger protein RING E3 ligase, holds potential as a tool to distinguish ROs from its mimickers, like chRCCs 50. Additionally, RO has significantly higher expression of the cancer-testis antigens (CTAs), such as MAGE-A3/4 and NY-ESO-1 51. Further investigation is needed to evaluate the potential diagnostic implications for these markers.…”

Section: Pathologymentioning

confidence: 99%

Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem?

Rajandram

Morais

et al. 2013

J Clin Pathol

View full text Add to dashboard Cite

Standard treatment of renal neoplasms remains surgical resection, and nephrectomy for localised renal cell carcinoma (RCC) still has the best chance of cure with excellent long-term results. For smaller renal masses, especially stage T1a tumours less than 4 cm, nephron-sparing surgery is often employed. However, small incidentally detected renal masses pose an important diagnostic dilemma as a proportion of them may be benign and could be managed conservatively. Renal oncocytoma is one such lesion that may pose little risk to a patient if managed with routine surveillance rather than surgery. Additionally, lower-risk RCC, such as small chromophobe RCC, may be managed in a similar way, although with more caution than the renal oncocytomas (RO). The ability to differentiate ROs from chromophobe RCCs, and from other RCCs with a greater chance of metastasis, would guide the physician and patient towards the most appropriate management, whether nephron-sparing surgical resection or conservative surveillance. Consistent accurate diagnosis of ROs is likely to remain elusive until modern molecular biomarkers are identified and applied routinely. This review focuses on the differentiation of renal oncocytomas and chromophobe RCCs. It summarises the history, epidemiology and clinical presentation of the renal neoplasms, explains the diagnostic dilemma, and describes the value, or not, of current molecular markers that are in development to assist in diagnosis of the renal neoplasms.

show abstract

“…One study, which included ten RCCs, reported the absence of NY-ESO-1 expression as analyzed by IHC [14]. Another study showed that NY-ESO-1 was expressed in 6 of 18 chromophobe RCCs and 15 of 17 oncocytomas [33]. Conflicting results were obtained by Bolli et.…”

Section: Introductionmentioning

confidence: 99%

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma

et al. 2014

View full text Add to dashboard Cite

Background: Novel immune therapies targeting tumor specific antigens are being developed. Our purpose was to determine expression of the cancer testes antigen NY-ESO-1 in renal cell carcinoma (RCC), as NY-ESO-1 targeting approaches, particularly adoptive cell therapy, have not been evaluated in this disease.Methods: We employed tissue microarrays containing >300 unique RCC cases and adjacent benign renal tissue to determine NY-ESO-1 expression using a quantitative immunofluorescence method. In addition, we studied NY-ESO-1 expression in 35 matched primary and metastatic RCC specimens to assess concordance between different tumor sites.Results: NY-ESO-1 was highly expressed in a subset of RCCs. Expression in primary RCC specimens was significantly higher than adjacent normal renal tissue (P<0.0001) and higher in clear cell carcinomas than papillary RCC (P<0.0001). Expression levels in metastatic specimens were higher than in matched primary samples (P=0.0018), and the correlation between the two sites was modest (χ2=3.5, p=0.06).Conclusions: Aberrant NY-ESO-1 expression seen in clear cell RCC suggests that NY-ESO-1 targeting approaches should be studied in this disease. Expression is higher in metastatic sites, and discordance between primary and metastatic sites in some patients suggests that patient selection for these therapies should be based on expression in metastatic rather than nephrectomy specimens.

show abstract

Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma

Cited by 14 publications

References 24 publications

Limited expression of cancer-testis antigens in renal cell carcinoma patients

Limited expression of cancer-testis antigens in renal cell carcinoma patients

Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem?

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma

Contact Info

Product

Resources

About